Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 10/20 | 0.77 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.77 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199795 | 0.90 | MAPK13 (0.74) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2197489 | 0.87 | KMT2A (0.60) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL6655015 | 0.87 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2197842 | 0.87 | MAPK14 (0.79) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2198908 | 0.86 | MAPK13 (0.68) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2200233 | 0.85 | MAPK13 (0.66) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL6657882 | 0.84 | MAPK13 (0.73) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL6658543 | 0.84 | MAPK13 (0.80) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2196335 | 0.83 | MAPK14 (0.76) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL16634680 | 0.83 | MAPK13 (0.71) | MAPK13MAPK12MAPK11MAPK14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658263-B9 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2011-11-09 | — | — | EP | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| EP-1658263-B1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.